Full video transcriptClick to expand
Auto-generated transcript of @drnighatarif's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00What are my thoughts about GLP1 weight loss injections and those living with PCOS?
- 0:05So weight loss injections we're talking about, as ampec, wagovii, and windjaro.
- 0:09There's data around about them.
- 0:11A lot of my patients are using them, in fact, so I actually found a lot of my PCOS patients
- 0:16who are taking them losing weight and becoming pregnant.
- 0:19So great news, but what does the data show?
- 0:22For any of you living with PCOS and you want to know what the treatment and the management
- 0:25is with meta-analysis and data back, I highly recommend the International Evidence
- 0:29based guidelines for the assessment and management of polycystic ovary syndrome because they have
- 0:34done a huge international assessment and then try to come up with sensible guidelines for
- 0:40patients who are living with PCOS.
- 0:41In the updated guidelines, there is a section on anti-abesity agents because they recognize
- 0:46that those living with insulin resistant PCOS, it's actually very difficult to try and lose
- 0:51weight because excess weight is a major concern and leads onto a whole cascade of other conditions.
- 0:57And in summary, what they said is we recommend using anti-abesity agents in PCOS for reproductive
- 1:02outcomes only in research settings and they are trying to establish further efficacy and
- 1:08studies to be done.
- 1:09But there's also been another data that's come out just lately in 2025.
- 1:13So this paper in 2025, we looked at the efficacy and safety of GLP1 weight loss injections for
- 1:18weight management in PCOS patients and it was a meta-analysis of randomized controlled trials.
- 1:23And it showed promise from the few trials that we've got, let's be honest, we don't
- 1:28have that many, they showed that it was worth considering for patients who are obese and
- 1:32also who have other health conditions which are impacting them and living with PCOS.
- 1:37For those living with insulin resistant PCOS, which affects about 70% of PCOS women and
- 1:43girls, then it is where women and girls struggle with that condition to maintain their weight
- 1:48leading to obesity.
- 1:49Now obesity is a chronic disease which leads onto type 2 diabetes, cardiovascular disease,
- 1:54non-alcoholic fatty liver disease and endometrial hyperplasia.
- 1:57PCOS is a whole body lifelong hormonal disease which is not just a bit of cysts on the ovaries
- 2:02and it has long-term implications for other chronic diseases.
- 2:06Currently, GLP1 weight loss injections are used off-license for insulin resistant PCOS patients
- 2:11and this is something that patients are doing privately as it's not available for PCOS patients
- 2:16in the NHS where there is a strict criteria for those that are needing weight loss GLP1
- 2:22injections.
- 2:23Although the data shows that quite a lot of promise for using GLP1 injections for PCOS,
- 2:29unfortunately we don't have long-term safety data yet.
- 2:32All the long-term data for how it will impact those living with PCOS which is actually a lifelong
- 2:38condition.
- 2:39Do you stay on GLP1 injections lifelong?
- 2:42I don't know, we just don't have the data for that and we need more studies.
- 2:46Give me your thoughts and experiences in the comments.
GLP-1s for PCOS insulin resistance: helpful tool, not a cure
Quick answer
GLP-1 receptor agonists are being used off-label for insulin-resistant PCOS to address weight, metabolic dysfunction, and androgen excess, with early RCT data suggesting modest benefit. The 2023 International PCOS Guidelines recommend their use only within research settings for reproductive outcomes, reflecting the lack of long-term safety data. Clinicians prescribing these agents to PCOS patients of reproductive age must address discontinuation protocols before conception, as both semaglutide and tirzepatide carry pregnancy warnings based on animal reproductive toxicity data.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1s for PCOS insulin resistance: helpful tool, not a cure, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1s for PCOS insulin resistance: helpful tool, not a cure is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1s for PCOS insulin resistance: helpful tool, not a cure" from Nighat Arif. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists are being used off-label for insulin-resistant PCOS to address weight, metabolic dysfunction, and androgen excess, with early RCT data suggesting modest benefit.
The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to it s b nana glp 1 s for insulin resistance pcos." In this clip, the useful excerpt is: "What are my thoughts about GLP1 weight loss injections and those living with PCOS?" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonists are being used off-label for insulin-resistant PCOS to address weight, metabolic dysfunction, and androgen excess, with early RCT data suggesting modest benefit.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists are being used off-label for insulin-resistant PCOS to address weight, metabolic dysfunction, and androgen excess, with early RCT data suggesting modest benefit. The 2023 International PCOS Guidelines recommend their use only within research settings for reproductive outcomes, reflecting the lack of long-term safety data. Clinicians prescribing these agents to PCOS patients of reproductive age must address discontinuation protocols before conception, as both semaglutide and tirzepatide carry pregnancy warnings based on animal reproductive toxicity data.
- The 2023 International PCOS Guidelines (Teede et al., Human Reproduction) recommend GLP-1 use for reproductive outcomes in PCOS only within research settings, not as standard clinical care.
- A 2024 meta-analysis of GLP-1 trials in PCOS found significant reductions in BMI, fasting insulin, and testosterone, but trials were small, short, and mostly used liraglutide rather than semaglutide or tirzepatide.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- The 2023 International PCOS Guidelines (Teede et al., Human Reproduction) recommend GLP-1 use for reproductive outcomes in PCOS only within research settings, not as standard clinical care.
- A 2024 meta-analysis of GLP-1 trials in PCOS found significant reductions in BMI, fasting insulin, and testosterone, but trials were small, short, and mostly used liraglutide rather than semaglutide or tirzepatide.
- Insulin resistance prevalence in PCOS is estimated at 50-80% depending on criteria used; the 70% figure cited is a reasonable central estimate, not a precise number.
- Semaglutide and tirzepatide carry pregnancy warnings based on animal reproductive toxicity data and should be discontinued at least two months before attempting conception.
- GLP-1 drugs are used off-label for PCOS in the UK and are not available via the NHS for this indication; access is currently through private prescribing only.
- Weight loss through GLP-1s can restore ovulatory function in some women with obesity-related PCOS, but this addresses a downstream metabolic symptom and does not resolve the underlying endocrine condition.
- No study has yet established whether metabolic improvements from GLP-1 therapy in PCOS persist after the drug is discontinued, a critical question for a lifelong condition in reproductive-age women.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @drnighatarif actually say?
Dr. Arif's core argument is measured: GLP-1 receptor agonists like semaglutide and tirzepatide show promise for insulin-resistant PCOS, particularly for weight management and reproductive outcomes, but the data is thin and long-term safety is unknown. She cited the International Evidence-Based Guidelines for PCOS and a 2025 meta-analysis of randomized controlled trials. She was also careful to note these drugs are used "off-license" for PCOS in the UK and are not available through the NHS for this indication. Her conclusion was essentially: interesting signal, not enough data, don't call it a cure.
She also made an observational point worth flagging: several of her PCOS patients on GLP-1s lost weight and became pregnant. That's anecdote, not evidence, and she didn't frame it as anything more than that, which is fair.
Does the science back this up?
Broadly, yes. The 2025 meta-analysis she references aligns with what's currently published. A 2024 meta-analysis by Jensterle et al. in the journal Reproductive Biology and Endocrinology found GLP-1 receptor agonists significantly reduced BMI, fasting insulin, and testosterone levels in women with PCOS compared to controls, but the trials were small and short. The International PCOS Guideline Network (Teede et al., 2023, Human Reproduction) does recommend anti-obesity agents in PCOS only within research settings for reproductive outcomes, exactly as she stated.
Her 70% insulin resistance prevalence figure is in the right ballpark. Published estimates range from 50% to 80% depending on the diagnostic criteria used (Diamanti-Kandarakis and Dunaif, 2012, Endocrine Reviews). Saying "about 70%" is a reasonable middle estimate, not a fabrication.
What did they get wrong (or right)?
She got the headline right: GLP-1s are not a cure for PCOS. Full stop. PCOS is a complex endocrine condition with genetic, metabolic, and reproductive dimensions. Weight loss, even significant weight loss, does not resolve the underlying hormonal dysregulation in most patients. She said as much, which deserves credit.
What she could have done better: she mentioned patients "becoming pregnant" after starting GLP-1s without flagging that semaglutide and tirzepatide carry a pregnancy warning. Both drugs should be discontinued at least two months before attempting conception per manufacturer guidance, and there are no adequate human pregnancy safety studies. The FDA labels for Ozempic and Wegovy explicitly note potential fetal harm based on animal data. Listing pregnancy as a positive outcome without this context is a meaningful omission for a video targeting people with a fertility-related condition.
She also described the 2025 meta-analysis as showing "promise from the few trials we've got," which is honest. But she didn't mention that most existing RCTs on GLP-1s in PCOS use liraglutide, not semaglutide or tirzepatide, so direct extrapolation to the newer drugs she named has limits.
What should you actually know?
If you have PCOS and you're thinking about GLP-1 therapy, here's what the current evidence actually supports. GLP-1 receptor agonists can produce meaningful weight loss and improve metabolic markers like fasting insulin and androgen levels in women with PCOS. That's real. But none of these drugs are approved specifically for PCOS anywhere, meaning use is off-label and should involve a specialist who knows your full picture.
The fertility question is genuinely complicated. Weight loss through any means, including GLP-1s, can restore ovulatory function in women with obesity-related PCOS. But GLP-1 drugs must be stopped before conception, and no one knows yet whether the metabolic improvements outlast the drug once it's discontinued. That's not a minor gap. For a lifelong condition in people of reproductive age, it's one of the most important questions in the field and it remains unanswered.
- Do not use GLP-1s during pregnancy or when actively trying to conceive without direct specialist guidance.
- These drugs address metabolic symptoms of PCOS, not its root cause.
- Long-term data on PCOS-specific outcomes simply does not exist yet for semaglutide or tirzepatide.
- NHS eligibility criteria for GLP-1s are based on BMI and comorbidities, not PCOS diagnosis.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Nighat Arif · TikTok creator
205.3K views on this video
Replying to @🍌 It's B'nana🍌 GLP-1’s for Insulin Resistance PCOS shows it helps but is not the cure. GLP1’s are anti-obesity agents which have side effects & we need long term data
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about the 2023 international pcos guidelines (teede et al., human reproduction)?
The 2023 International PCOS Guidelines (Teede et al., Human Reproduction) recommend GLP-1 use for reproductive outcomes in PCOS only within research settings, not as standard clinical care.
What does the video say about a 2024 meta-analysis of glp-1 trials in pcos found significant?
A 2024 meta-analysis of GLP-1 trials in PCOS found significant reductions in BMI, fasting insulin, and testosterone, but trials were small, short, and mostly used liraglutide rather than semaglutide or tirzepatide.
What does the video say about insulin resistance prevalence in pcos?
Insulin resistance prevalence in PCOS is estimated at 50-80% depending on criteria used; the 70% figure cited is a reasonable central estimate, not a precise number.
What does the video say about semaglutide?
Semaglutide and tirzepatide carry pregnancy warnings based on animal reproductive toxicity data and should be discontinued at least two months before attempting conception.
What does the video say about glp-1 drugs?
GLP-1 drugs are used off-label for PCOS in the UK and are not available via the NHS for this indication; access is currently through private prescribing only.
What does the video say about weight loss through glp-1s can restore ovulatory function in some?
Weight loss through GLP-1s can restore ovulatory function in some women with obesity-related PCOS, but this addresses a downstream metabolic symptom and does not resolve the underlying endocrine condition.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Nighat Arif, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.